

September 21, 2001 Reference No. FDAA01018

VIA FEDERAL EXPRESS 19:18

Dockets Management Branch, HFA-305 Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

07

SUBJECT:

Request for Extension to Submit Comments for the Draft Guidance entitled, "Guidance for Industry: Revised Preventative Measures to Reduce the Possible Risk of Transmission of Creutzfedlt-Jacob Disease (CJD) and Variant Creutzfedlt-Jakob Disease (vCJD) by Blood and Blood Products (August 2001)," Docket No. 97D-0318

Dear Sir or Madam:

PPTA is requesting a two-week extension for the submission of comments on the Draft Guidance entitled, "Guidance for Industry: Revised Preventative Measures to Reduce the Possible Risk of Transmission of Creutzfedlt-Jacob Disease (CJD) and Variant Creutzfedlt-Jakob Disease (vCJD) by Blood and Blood Products (August 2001)," Docket No. 97D-0318. As a result of the tragic events of last week in New York, Washington, and Pennsylvania, industry is requesting this additional time to submit comments on this important issue.

Should you have any questions, please contact me at 410.263.8296. Thank you for your consideration.

Respectfully,

Christopher Healey

Executive Director, PPTA North America

TLL

970-0318

D EXT 2 CHRISTOPHER HEALEY
D O ASSOCIATION OFFICE
147 OLD SOLOMONS ISLAND ROAD
ANNAPOLIS MD 21401
(410)268-2011

SHIP DATE: 21SEP01 ACCOUNT # 102735463 MAN-WGT:1 LBS

TO: FDA
DOCKETS MANAGEMENT BRANCH, HFA-305
5630 FISHERS LANE
ROOM 1061
ROCKVILLE MD 20852

337 0913 253

FecExx.

POWERSHIP 3

op on the control of the control of

BILL 3rd PARTY

REF: PPTA EXTENSION COMMENTS FOR CJD

PRIORITY OVERNIGHT

MON

CAD # 74414

21SEP01

Trk# 337 0913 253

FedEx Letter

DROP 20852-MD-US <u> 19ĞAI</u>

153077 RIT 04/0